• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

评估 IPPSE,一种用于序贯群体 PKPD 分析的替代方法。

Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.

机构信息

Pharmacometrics Group, Dept of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden.

出版信息

J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):177-93. doi: 10.1007/s10928-012-9240-x. Epub 2012 Jan 21.

DOI:10.1007/s10928-012-9240-x
PMID:22270323
Abstract

The aim of this study is to present and evaluate an alternative sequential method to perform population pharmacokinetic-pharmacodynamic (PKPD) analysis. Simultaneous PKPD analysis (SIM) is generally considered the reference method but may be computationally burdensome and time consuming. Evaluation of alternative approaches aims at speeding up the computation time and stabilizing the estimation of the models, while estimating the model parameters with good enough precision. The IPPSE method presented here uses the individual PK parameter estimates and their uncertainty (SE) to propagate the PK information to the PD estimation step, while the IPP method uses the individual PK parameters only and the PPP&D method utilizes the PK data. Data sets (n = 200) with various study designs were simulated according to a one-compartment PK model and a direct Emax PD model. The study design of each dataset was randomly selected. The same PK and PD models were fitted to the simulated observations using the SIM, IPP, PPP&D and IPPSE methods. The performances of the methods were compared with respect to estimation precision and bias, and computation time. Estimated precision and bias for the IPPSE method were similar to that of SIM and PPP&D, while IPP had higher bias and imprecision. Compared with the SIM method, IPPSE saved more computation time (61%) than PPP&D (39%), while IPP remained the fastest method (86% run time saved). The IPPSE method is a promising alternative for PKPD analysis, combining the advantages of the SIM (higher precision and lower bias of parameter estimates) and the IPP (shorter run time) methods.

摘要

本研究旨在提出并评估一种替代的序贯方法来进行群体药代动力学-药效学(PKPD)分析。同时进行 PKPD 分析(SIM)通常被认为是参考方法,但可能计算量大且耗时。评估替代方法的目的是加快计算时间并稳定模型的估计,同时以足够好的精度估计模型参数。本文提出的 IPPSE 方法使用个体 PK 参数估计值及其不确定性(SE)将 PK 信息传播到 PD 估计步骤,而 IPP 方法仅使用个体 PK 参数,PPP&D 方法则利用 PK 数据。根据单室 PK 模型和直接 Emax PD 模型,根据各种研究设计模拟了数据集(n=200)。每个数据集的研究设计是随机选择的。使用 SIM、IPP、PPP&D 和 IPPSE 方法拟合相同的 PK 和 PD 模型到模拟观测值。比较了方法在估计精度和偏差以及计算时间方面的性能。IPPSE 方法的估计精度和偏差与 SIM 和 PPP&D 相似,而 IPP 的偏差和不精确性更高。与 SIM 方法相比,IPPSE 比 PPP&D 节省了更多的计算时间(61%),而 IPP 仍然是最快的方法(节省 86%的运行时间)。IPPSE 方法是 PKPD 分析的一种有前途的替代方法,结合了 SIM(更高的参数估计精度和更低的偏差)和 IPP(更短的运行时间)方法的优点。

相似文献

1
Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.评估 IPPSE,一种用于序贯群体 PKPD 分析的替代方法。
J Pharmacokinet Pharmacodyn. 2012 Apr;39(2):177-93. doi: 10.1007/s10928-012-9240-x. Epub 2012 Jan 21.
2
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.群体药代动力学/药效学数据的同步分析与序贯分析I:最佳情况表现
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404. doi: 10.1023/b:jopa.0000012998.04442.1f.
3
The use of the SAEM algorithm in MONOLIX software for estimation of population pharmacokinetic-pharmacodynamic-viral dynamics parameters of maraviroc in asymptomatic HIV subjects.利用 MONOLIX 软件中的 SAEM 算法估算无症状 HIV 受试者中马拉维若的群体药代动力学-药效学-病毒动力学参数。
J Pharmacokinet Pharmacodyn. 2011 Feb;38(1):41-61. doi: 10.1007/s10928-010-9175-z. Epub 2010 Nov 19.
4
Simultaneous vs. sequential analysis for population PK/PD data II: robustness of methods.群体药代动力学/药效学数据的同步分析与序贯分析II:方法的稳健性
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):405-16. doi: 10.1023/b:jopa.0000012999.36063.4e.
5
Simultaneous versus sequential pharmacokinetic-pharmacodynamic population analysis using an iterative two-stage Bayesian technique.使用迭代两阶段贝叶斯技术进行同步与序贯药代动力学-药效学群体分析。
Biopharm Drug Dispos. 2007 Nov;28(8):455-73. doi: 10.1002/bdd.575.
6
Deterministic identifiability of population pharmacokinetic and pharmacokinetic-pharmacodynamic models.群体药代动力学和药代动力学-药效学模型的确定性可识别性。
J Pharmacokinet Pharmacodyn. 2017 Oct;44(5):415-423. doi: 10.1007/s10928-017-9530-4. Epub 2017 Jun 13.
7
In silico predictions of gastrointestinal drug absorption in pharmaceutical product development: application of the mechanistic absorption model GI-Sim.在药物产品开发中的胃肠道药物吸收的计算预测:机制吸收模型 GI-Sim 的应用。
Eur J Pharm Sci. 2013 Jul 16;49(4):679-98. doi: 10.1016/j.ejps.2013.05.019. Epub 2013 May 29.
8
Designs for population pharmacodynamics: value of pharmacokinetic data and population analysis.群体药效学设计:药代动力学数据和群体分析的价值
J Pharmacokinet Biopharm. 1991 Jun;19(3):333-53. doi: 10.1007/BF03036255.
9
Simultaneous modeling of pharmacokinetics and pharmacodynamics with nonparametric kinetic and dynamic models.使用非参数动力学和动力学模型对药代动力学和药效学进行同时建模。
Clin Pharmacol Ther. 1986 Jul;40(1):86-93. doi: 10.1038/clpt.1986.143.
10
Impact of pharmacokinetic-pharmacodynamic model linearization on the accuracy of population information matrix and optimal design.药代动力学-药效学模型线性化对群体信息矩阵准确性和最优设计的影响。
J Pharmacokinet Pharmacodyn. 2001 Aug;28(4):363-88. doi: 10.1023/a:1011534830530.

引用本文的文献

1
Population pharmacokinetics/pharmacodynamics analysis confirming biosimilarity of SB16 to reference denosumab.群体药代动力学/药效学分析证实SB16与参比地诺单抗具有生物相似性。
Front Pharmacol. 2025 Aug 19;16:1631034. doi: 10.3389/fphar.2025.1631034. eCollection 2025.
2
In the Cradle of Pharmacometric Methodology: Introducing Population PKPD Modeling, Simultaneous Analysis, and the Effect-Compartment Model-Commentary on Sheiner et al.在药代动力学方法的摇篮中:介绍群体药代动力学-药效学建模、同步分析和效应室模型——对谢纳等人的评论
Clin Pharmacol Ther. 2025 Jun;117(6):1516-1532. doi: 10.1002/cpt.3663.
3
Population pharmacokinetic, pharmacodynamic and efficacy modeling of SB12 (proposed eculizumab biosimilar) and reference eculizumab.

本文引用的文献

1
Importance of shrinkage in empirical bayes estimates for diagnostics: problems and solutions.收缩在诊断的经验贝叶斯估计中的重要性:问题与解决方案。
AAPS J. 2009 Sep;11(3):558-69. doi: 10.1208/s12248-009-9133-0. Epub 2009 Aug 1.
2
PsN-Toolkit--a collection of computer intensive statistical methods for non-linear mixed effect modeling using NONMEM.PsN工具包——一组使用NONMEM进行非线性混合效应建模的计算机密集型统计方法。
Comput Methods Programs Biomed. 2005 Sep;79(3):241-57. doi: 10.1016/j.cmpb.2005.04.005.
3
Standardization of pharmacokinetic/pharmacodynamic (PK/PD) terminology for anti-infective drugs: an update.
SB12(拟生物类似药依库珠单抗)与参照药依库珠单抗的群体药代动力学、药效学和疗效建模。
Eur J Clin Pharmacol. 2024 Sep;80(9):1325-1338. doi: 10.1007/s00228-024-03703-8. Epub 2024 May 30.
4
Comparison of Two Methods for Determining Item Characteristic Functions and Latent Variable Time-Course for Pharmacometric Item Response Models.两种方法测定药代动力学项目反应模型项目特征函数和潜在变量时间进程的比较。
AAPS J. 2024 Jan 25;26(1):21. doi: 10.1208/s12248-023-00883-6.
5
C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.C反应蛋白作为晚期非小细胞肺癌患者疗效的早期预测指标:肿瘤动力学-生物标志物建模框架
Cancers (Basel). 2023 Nov 15;15(22):5429. doi: 10.3390/cancers15225429.
6
Population pharmacokinetics, pharmacodynamics and pharmacogenetics modelling of oxypurinol in Hmong adults with gout and/or hyperuricemia.黄嘌呤醇在患有痛风和/或高尿酸血症的苗族成年人中的群体药代动力学、药效学和药物遗传学建模。
Br J Clin Pharmacol. 2023 Oct;89(10):2964-2976. doi: 10.1111/bcp.15792. Epub 2023 Jun 4.
7
Bayesian forecasting of tumor size metrics and overall survival.贝叶斯预测肿瘤大小指标和总生存期。
CPT Pharmacometrics Syst Pharmacol. 2022 Dec;11(12):1604-1613. doi: 10.1002/psp4.12869. Epub 2022 Oct 4.
8
Inferring pulmonary exposure based on clinical PK data: accuracy and precision of model-based deconvolution methods.基于临床 PK 数据推断肺部暴露:基于模型的去卷积方法的准确性和精密度。
J Pharmacokinet Pharmacodyn. 2022 Apr;49(2):135-149. doi: 10.1007/s10928-021-09780-x. Epub 2021 Sep 28.
9
Item Response Theory Modeling of the International Prostate Symptom Score in Patients with Lower Urinary Tract Symptoms Associated with Benign Prostatic Hyperplasia.国际前列腺症状评分在良性前列腺增生相关下尿路症状患者中的项目反应理论建模。
AAPS J. 2020 Aug 27;22(5):115. doi: 10.1208/s12248-020-00500-w.
10
Model-Based Prediction of Plasma Concentration and Enterohepatic Circulation of Total Bile Acids in Humans.基于模型的人体总胆汁酸血药浓度和肠肝循环预测。
CPT Pharmacometrics Syst Pharmacol. 2018 Sep;7(9):603-612. doi: 10.1002/psp4.12325. Epub 2018 Aug 12.
抗感染药物药代动力学/药效学(PK/PD)术语的标准化:更新版
J Antimicrob Chemother. 2005 May;55(5):601-7. doi: 10.1093/jac/dki079. Epub 2005 Mar 16.
4
Simultaneous vs. sequential analysis for population PK/PD data I: best-case performance.群体药代动力学/药效学数据的同步分析与序贯分析I:最佳情况表现
J Pharmacokinet Pharmacodyn. 2003 Dec;30(6):387-404. doi: 10.1023/b:jopa.0000012998.04442.1f.
5
Population modelling in drug development.药物研发中的群体建模
Stat Methods Med Res. 1999 Sep;8(3):183-93. doi: 10.1177/096228029900800302.